BIOMAT Database Logo BIOMAT Database Logo

Synthesis, molecular docking, and biological activity of polyfluoroalkyl dihydroazolo[5,1-c][1,2,4]triazines as selective carboxylesterase inhibitors. 2017

Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Postovsky Institute of Organic Synthesis, Urals Branch of Russian Academy of Sciences, Yekaterinburg 620990, Russia.

To search for effective and selective inhibitors of carboxylesterase (CaE), a series of 7-hydroxy-7-polyfluoroalkyl-4,7-dihydroazolo[5,1-c][1,2,4]triazines has been synthesized. Their inhibitory activity against acetylcholinesterase, butyrylcholinesterase, and CaE were investigated using the methods of enzyme kinetics and molecular docking. It was shown that the tested compounds are reversible selective CaE inhibitors of mixed type. Elongation of the polyfluoroalkyl substituent and the presence of an ester, preferably the ethoxycarbonyl group, enhance inhibitory activity toward CaE. Furthermore, the compounds with a tetrazole ring are more active against CaE than their triazole analogues. The obtained kinetic data are well explained by the results of molecular docking, according to which there is a similar orientation of triazolo- and tetrazolotriazines in the active site of CaE and the opposite one for pyrazolotriazines. In the 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) assay, all of the studied tetrazolotriazines and some pyrazolotriazines demonstrated good antiradical activity comparable with a standard antioxidant, Trolox. The leading compounds were nonafluorobutyl substituted tetrazolo- and 7-phenylpyrazolotriazines, which possess effective and selective CaE inhibitory activity as well as additional useful radical-scavenging properties.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014227 Triazines Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazine,Benzotriazines
D043182 Carboxylesterase Carboxylesterase is a serine-dependent esterase with wide substrate specificity. The enzyme is involved in the detoxification of XENOBIOTICS and the activation of ester and of amide PRODRUGS. Ali-esterase,B-esterase,CAP-hydrolyzing Enzyme,Capsaicin-Hydrolyzing Enzyme,Carboxyesterase,Carboxylate Esterase,Carboxylester Lipase,Carboxylesterase B,Carboxylic Ester Hydrolase,Esterase 10,Esterase 13,Esterase 3,Esterase 6A,Esterase 8,Esterase ES-1A,Hydrolase S,Isocarboxazid amidase,Naproxen Esterase,Non-specific Carboxylesterase,Non-specific Esterase,Nonspecific Esterase,Procaine Esterase,Ali esterase,B esterase,CAP hydrolyzing Enzyme,Capsaicin Hydrolyzing Enzyme,Carboxylesterase, Non-specific,ES-1A, Esterase,Enzyme, CAP-hydrolyzing,Enzyme, Capsaicin-Hydrolyzing,Ester Hydrolase, Carboxylic,Esterase ES 1A,Esterase, Carboxylate,Esterase, Naproxen,Esterase, Non-specific,Esterase, Nonspecific,Esterase, Procaine,Hydrolase, Carboxylic Ester,Lipase, Carboxylester,Non specific Carboxylesterase,Non specific Esterase,amidase, Isocarboxazid
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1-c][1,2,4]-triazines and Pyrazolo[5,1-c][1,2,4]triazines as Potential Antidiabetic Agents.
May 2017, Archiv der Pharmazie,
Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Isoxazolyl-Derived 1,4-Dihydroazolo[5,1-c][1,2,4]Triazines: Synthesis and Photochemical Properties.
April 2023, Molecules (Basel, Switzerland),
Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
4-Hydroxy-3-nitro-1,4-dihydrotriazolo[5,1-c][1,2,4]triazines: synthesis, antiviral activity, and electrochemical characteristics.
January 2022, Russian chemical bulletin = Izvestiia Akademii nauk. Seriia khimicheskaia,
Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Synthesis of new pyrazolo[5,1-c][1,2,4] benzotriazines, pyrazolo[5,1-c]pyrido[4,3-e][1,2,4] triazines and their open analogues as cytotoxic agents in normoxic and hypoxic conditions.
November 2008, Bioorganic & medicinal chemistry,
Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Synthesis and crystal structures of 7,8-bromo (dibromo)-3-tert-butylpyrazolo[5,1-c][1,2,4]triazines.
January 2021, Structural chemistry,
Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Synthesis, Characterization, Antimicrobial Activity and Anticancer of Some New Pyrazolo[1,5-a]pyrimidines and Pyrazolo[5,1-c]1,2,4-triazines.
January 2020, Medicinal chemistry (Shariqah (United Arab Emirates)),
Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Synthesis, Molecular Docking, and Biological Evaluation of Benzimidazole Derivatives as Selective Butyrylcholinesterase Inhibitors.
January 2020, Current Alzheimer research,
Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Pyridazine derivatives and related compounds. Part 13: Synthesis and antimicrobial activity of some pyridazino[3',4':3,4]pyrazolo[5,1-c]-1,2,4-triazines.
October 2004, Bioorganic & medicinal chemistry letters,
Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Synthesis, biological activity and molecular modeling study of novel 1,2,4-triazolo[4,3-b][1,2,4,5]tetrazines and 1,2,4-triazolo[4,3-b][1,2,4]triazines.
April 2020, Scientific reports,
Evgeny V Shchegol'kov, and Galina F Makhaeva, and Natalia P Boltneva, and Sofya V Lushchekina, and Olga G Serebryakova, and Elena V Rudakova, and Nadezhda V Kovaleva, and Yanina V Burgart, and Victor I Saloutin, and Oleg N Chupakhin, and Sergey O Bachurin, and Rudy J Richardson
Synthesis, molecular docking, and biological evaluation of 3-oxo-2-tolylhydrazinylidene-4,4,4-trifluorobutanoates bearing higher and natural alcohol moieties as new selective carboxylesterase inhibitors.
October 2019, Bioorganic chemistry,
Copied contents to your clipboard!